AHA GUIDELINES Bundle (free trial)

Blood Cholesterol

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512420

Contents of this Issue

Navigation

Page 13 of 31

14 Diagnosis 4.4.2. Primary Prevention Adults 40 to 75 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.7 to 4.8 mmol/L) COR LOE Recommendations I A 1. In adults at intermediate-risk, statin therapy reduces risk of ASCVD, and in the context of a risk discussion, if a decision is made for statin therapy, a moderate-intensity statin should be recommended. I A 2. In intermediate-risk patients, LDL-C levels should be reduced by 30% or more, and for optimal ASCVD risk reduction, especially in high-risk patients, levels should be reduced by 50% or more. I B-NR 3. For the primary prevention of clinical ASCVD a in adults 40 to 75 years of age without diabetes mellitus and with an LDL-C level of 70 to 189 mg/dL (1.7 to 4.8 mmol/L), the 10-year ASCVD risk of a first "hard" ASCVD event (fatal and nonfatal MI or stroke) should be estimated by using the race- and sex-specific pooled cohort equation (PCE), and adults should be categorized as being at low risk (<5%), borderline risk (5% to <7.5%), intermediate-risk (≥7.5% to <20%), and high-risk (≥20%). I B-NR 4. Clinicians and patients should engage in a risk discussion that considers risk factors, adherence to healthy lifestyle, the potential for ASCVD risk-reduction benefits, and the potential for adverse effects and drug-drug interactions, as well as patient preferences, for an individualized treatment decision. IIa B-R 5. In intermediate-risk adults, risk-enhancing factors favor initiation or intensification of statin therapy. IIa B-NR 6. In intermediate-risk or selected borderline-risk adults, if the decision about statin use remains uncertain, it is reasonable to use a CAC score in the decision to withhold, postpone or initiate statin therapy. IIa B-NR 7. In intermediate-risk adults or selected borderline-risk adults in whom a CAC score is measured for the purpose of making a treatment decision, AND • If the coronary calcium score is zero, it is reasonable to withhold statin therapy and reassess in 5 to 10 years, as long as higher risk conditions are absent (diabetes mellitus, family history of premature CHD, cigarette smoking ); • If CAC score is 1 to 99, it is reasonable to initiate statin therapy for patients ≥ 55 years of age; • If CAC score is 100 or higher or in the 75th percentile or higher, it is reasonable to initiate statin therapy.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Blood Cholesterol